Trial Profile
Phase I/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-CHOP in a Cohort of Patients With DLBCL/tFL/ High Grade B-NHL
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Nivolumab (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 Dec 2023 Results evaluating safety and preliminary efficacy nivolumab in combination with R-CHOP in pts with DLBCL, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 11 Aug 2022 Planned End Date changed from 11 Jun 2023 to 11 Jun 2025.
- 11 Aug 2022 Planned primary completion date changed from 11 May 2022 to 11 Dec 2024.